Vicore Pharma Holding AB
No SEC Form 4 filings for $VCRE in the last 30 days.
See all $VCRE insider activity →Biohaven (BHVN) +31% after FDA accepted resubmitted drug application for spinocerebellar ataxia. Korro Bio (KRRO) +25% on positive preclinical results for AATD treatment. Actinium (ATNM) +18% with initial Phase 1 data for prostate cancer radiotherapy. Vicore (VCRE) +16% after passing IPF trial futility analysis.
Vicore Pharma's (VICO) Phase 2b ASPIRE trial of buloxibutid in IPF will continue as planned after a positive futility review. The 378-patient trial is fully enrolled and expects topline results in mid-2027. No safety concerns were identified.
Jefferies initiated coverage of Vicore Pharma (VCRE) with a buy rating and $25 price target, citing potential in idiopathic pulmonary fibrosis treatment. The stock has fallen 46% in six months but analysts predict profitability this year with an EPS of $0.53. Jefferies notes favorable setup ahead of 2027 Phase 2b trial data.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning VCRE (Vicore Pharma Holding AB). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent VCRE coverage spans financial news, market movers and corporate actions.
Trial continuation suggests the drug remains on track for 2027 topline data.
Vicore Pharma's (VICO) Phase 2b ASPIRE trial of buloxibutid in IPF will continue as planned after a positive futility review. The 378-patient trial is fully enrolled and expects topline results in mid-2027. No safety concerns were identified.
Analyst initiation and high upside target may drive buying interest.
This appears to be momentum mean reversion rather than new information.
The appointment is a structural market-access update for Vicore’s ADRs; it can modestly affect liquidity/visibility but is not a fundamental operating change.
AlphAI scores every news story that mentions VCRE with an AI model for sentiment and relevance, and aggregates insider trades from Vicore Pharma Holding AB's SEC EDGAR Form 4 filings. Figures refresh continuously.
Biohaven (BHVN) +31% after FDA accepted resubmitted drug application for spinocerebellar ataxia. Korro Bio (KRRO) +25% on positive preclinical results for AATD treatment. Actinium (ATNM) +18% with initial Phase 1 data for prostate cancer radiotherapy. Vicore (VCRE) +16% after passing IPF trial futility analysis.
2 min readVicore Pharma's (VICO) Phase 2b ASPIRE trial of buloxibutid in IPF will continue as planned after a positive futility review. The 378-patient trial is fully enrolled and expects topline results in mid-2027. No safety concerns were identified.
1 min readJefferies initiated coverage of Vicore Pharma (VCRE) with a buy rating and $25 price target, citing potential in idiopathic pulmonary fibrosis treatment. The stock has fallen 46% in six months but analysts predict profitability this year with an EPS of $0.53. Jefferies notes favorable setup ahead of 2027 Phase 2b trial data.
1 min readU.S. stock futures were mixed. Evolution Metals & Technologies (EMAT) fell in pre-market after reporting Q2 losses of 2 cents per share, beating consensus of 3 cents, but sales of $1.636M missed $2.100M; shares fell 5.5% to $2.86. Barfresh (BRFH) dropped 24% after weaker Q2 results and lowered FY26 sales guidance. Snap (SNAP) fell about 15% to $4.62.
3 min readCiti Issuer Services (Citibank N.A.) was appointed depositary bank for Vicore Pharma Holding AB’s sponsored Level 2 ADR program. Vicore Pharma ADRs trade on Nasdaq Capital Market under VCRE, with each ADS representing 10 ordinary shares; ordinary shares trade on Nasdaq Stockholm as VICO. Citi cited its ADR services and global network.
2 min readVicore Pharma said its ADSs will begin trading in the U.S. on Nasdaq after the SEC declared its Form 20-F registration effective and Nasdaq approved the listing. The Nasdaq U.S. listing is secondary and involves no capital raise or new shares; Citi is the depositary bank. Vicore Pharma trades on Nasdaq Stockholm as VICO and Nasdaq U.S. as VCRE.
2 min read
